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Abstract Tumor necrosis factor-related apoptosis-induc-
ing ligand (TRAIL), delivered as a membrane-bound mole-
cule expressed on the surface of adenovirus-transduced
CD34? cells (CD34-TRAIL?), was analyzed for its apop-
totic activity in vitro on 12 breast cancer cell lines repre-
senting estrogen receptor-positive, HER2? and triple-
negative (TN) subtypes and for its effect on tumor growth,
vascularization, necrosis, and lung metastasis incidence in
NOD/SCID mice xenografted with the TN breast cancer line
MDA-MB-231. Mesenchymal TN cell lines, which are the
richest in putative tumor stem cells among the different
breast cancer cell subtypes, were the most susceptible to
apoptosis induced by CD34-TRAIL? cells. Indeed, tumor
cell ‘‘stemness’’, assessed based on the proportion of CD44?/
CD24-/low cells, was significantly correlated with suscepti-
bility to TRAIL. Moreover, in vitro cytotoxicity experiments
showed that CD34-TRAIL? cells selectively targeted
CD44?/CD24-/low cells. Although in vivo treatment with
CD34-TRAIL? cells did not lead to tumor growth inhibition,
treated mice revealed significantly larger areas of necrosis
associated with damage of tumor vasculature than did con-
trol mice. Moreover, lungs from MDA-MD-231 tumor-
bearing mice were completely free of metastases at 12 days
after the last injection of CD34-TRAIL? cells, whereas
metastases were present in all control mouse lungs. An anti-
metastatic effect of CD34-TRAIL? cells was also observed
in a model of experimental lung metastases. The correlation
between in vitro susceptibility to membrane-bound TRAIL
and tumor stem cell content, together with CD34-TRAIL?
cell-induced inhibition of the metastatic process, points to
the selective targeting of cancer stem cells by CD34-armed
cells and the potential value of such cells in eradicating
tumor stem cells before the onset of overt metastases.
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Introduction
In the last years, significant progress has been made in the
understanding of the cellular pathways regulating cell death
and in therapeutic strategies to promote tumor cell death.
Two major apoptotic pathways have been characterized, one
of which is activated by changes in mitochondrial
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permeability (intrinsic pathway) and the second, triggered by
cell surface death receptors engaging specific ligands
(extrinsic pathway) [1]. Activation of the death receptor
pathway results in recruitment of adaptor molecules and
caspase-8 to form the death-inducing signaling complex,
thereby inducing caspase-3 activation and apoptosis [2, 3].
Among the ligands that activate the extrinsic pathway, tumor
necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL), a type II transmembrane protein in the TNF
superfamily of death receptor ligands [4], is considered a
prime candidate for clinical application based on its ability to
induce apoptosis in a panel of hematological cancer cell lines
and its minimal toxicity to normal human cells [5]. Recently,
Carlo-Stella et al. [6] showed that CD34? cells transduced
with adenovirus to express TRAIL as a membrane-bound
molecule on the cell surface (CD34-TRAIL? cells) exert a
potent anti-lymphoma activity. Genetically modified CD34?
stem cells represent optimal vehicles for delivering anti-
tumor molecules because they are susceptible to adenoviral
infection [7] and can migrate from the bloodstream into
several tissues, including tumors [8], and because CD34?
cells express adhesion receptors that interact with counter-
receptors on endothelial cells in the tumor microenviron-
ment [9–11], where the presence of inflammatory chemoat-
tractants might help to promote efficient tumor targeting of
systemically delivered stem cells [12, 13].
To address the potential therapeutic usefulness of CD34-
TRAIL? cells in breast cancer patients and to help identify
the breast tumor subtypes likely to benefit clinically from
these cells, we analyzed their pro-apoptotic activity and the
possible correlation between sensitivity and expression of
four death receptors, TRAIL-R1, -R2, -R3, and -R4, in breast
carcinoma cell lines representing the genetic heterogeneity
present in primary breast cancer. We then analyzed the anti-
tumor activity of CD34-TRAIL? cells in a xenograft model.
We found that membrane-bound TRAIL induced significant
cell death in several breast cancer cell lines, especially in
triple-negative (TN) lines with mesenchymal features, and
that sensitivity to CD34-TRAIL? cells positively correlated
with the proportion of cancer stem cells. Moreover, CD34-
TRAIL? cell treatment prevented development of sponta-
neous lung metastases in mice bearing subcutaneously (s.c.)
injected TN breast tumor cells.
Materials and methods
Cell lines and CD34? cells
Human breast cancer cell lines (obtained from ATCC) were
maintained in: RPMI-1640 (MCF-7, MDA-MB-231, SKBr3,
T47D, HCC-1937, and ZR-75-1); Dulbecco’s modified
Eagle’s medium (DMEM) (BT-474); Leibowitz L-15 (MDA-
MB-361, MDA-MB-157, MDA-MB-468, and MDA-MB-
453); and DMEM-F12 (SUM-159) supplemented with 10 %
fetal bovine serum. Culture medium for SUM-159 cells was
also supplemented with 5 lg/ml insulin and that of HCC-1937
and ZR-75-1 cells with 1 % sodium pyruvate, 1 % non-
essential amino acids, and 1 % HEPES. Cell lines were rou-
tinely tested for mycoplasma and cellular contamination or
misidentification using STR analysis (DNA analysis).
CD34? cells were positively selected using the Auto-
MACS device (Miltenyi Biotec, Bergisch-Gladbach, Ger-
many, EU) from peripheral blood of consenting donors of
allogeneic stem cells undergoing peripheral blood stem cell
mobilization with hematopoietic growth factors.
Adenoviral transduction of CD34? cells
A replication-deficient adenovirus encoding the human
TRAIL gene (Ad-TRAIL) expressed from the CMV promoter
was generated as described [14] using human TRAIL cDNA
purchased from the Riken BioResource Center (Tsukuba,
Ibaraki, Japan) [15]. CD34? cells were plated at 2 9 106/ml
in 1 ml of serum-free Iscove’s modified Dulbecco’s medium
(IMDM) containing an appropriate dilution of adenovector
stock for a final MOI of 200 plaque-forming units (pfu)/cell.
After incubation at 37 C in 5 % CO2 for 2 h, cultures were
supplemented with 1 ml IMDM plus FBS 20 % and Boo-
sterExpressTM reagent (Gene Therapy Systems, San Diego,
CA, USA) (final dilution 1:200) and incubated for 18 h,
extensively washed in serum-containing medium, and eval-
uated for transduction efficiency by flow cytometry.
Flow cytometry
For analysis of Ad-TRAIL transduction efficiency of
CD34? cells, cells were incubated with phycoerythrin
(PE)-conjugated anti-TRAIL antibody [clone Rik-2; Bec-
ton–Dickinson (B-D), San Jose, CA, USA] and allophyc-
ocyanin (APC)-conjugated CD34 antibody (B-D).
Expression of TRAIL receptors on the surface of all breast
cancer cell lines (1 9 106) was examined using PE-anti-
TRAIL-R1, -R2 -R3, and -R4 antibodies (R&D Systems,
Minneapolis, MN, USA) and the appropriate isotype con-
trols (B-D and R&D Systems). Samples were analyzed on a
FACSCalibur flow cytometry system (B-D) using Cell
Quest (B-D) software. Expression levels of TRAIL recep-
tors are indicated as the ratio between the mean fluores-
cence intensity of anti-TRAIL receptor-stained samples
and that of isotype control-stained samples.
The content of putative cancer stem cells (CD44?/
CD24-/low) in the breast cancer cell lines was evaluated in
tumor single-cell suspensions (1 9 106) labeled with PE-
conjugated CD24 antibody (clone ML-5; B-D), FITC-
conjugated CD44 antibody (clone G44-26; B-D) or the
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appropriate isotype controls (B-D) according to the man-
ufacturer’s instructions. Samples were analyzed by
FACSCanto II system (B-D) and analyzed using FlowJo
Software (TreeStar Inc., Ashland, OR, USA).
Analysis of CD34-TRAIL? cell and soluble TRAIL
activity in vitro
Tumor cells were left untreated, treated with soluble TRAIL
(sTRAIL) (100 ng/ml) (Alexis Corporation, Lausen, Swit-
zerland), or co-cultured with CD34-TRAIL? cells at 1:1
effector/target cell ratio for 48 h. The percentage of cell
death was calculated based on Annexin-V/propidium iodide
(PI) double-staining using the Annexin-V-FITC assay
(Bender MedSystems, San Bruno, CA, USA). In brief, cells
were washed twice with cold PBS, resuspended in binding
buffer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl2, pH
7.4), and incubated with Annexin-V-FITC for 10 min at
room temperature in the dark. At the end of the incubation,
PI was added and cells were immediately analyzed by flow
cytometry. Annexin-V/PI double-staining allows the quan-
titation of apoptotic (Annexin-V?/PI-) and non-apoptotic,
i.e., dead cells (Annexin-V?/PI? plus Annexin-V-/PI?).
In co-culture experiments, the percentages of residual
viable CD44?/CD24-/low cells were calculated to evaluate
whether the cytotoxic activity of CD34-TRAIL? cells
might selectively target CD44?/CD24-/low putative cancer
stem cells. In brief, cells were washed with cold PBS,
stained with PE-conjugated CD24 antibody (B-D) and
FITC-conjugated CD44 antibody (B-D), and viable cells
gated using 7-AAD staining solution (B-D). To exclude
CD34-TRAIL? cells in the estimation of apoptosis and
necrosis and of percentages of viable cells, co-cultures
were concurrently stained with APC-conjugated anti-CD45
monoclonal antibody (B-D), which labels CD34? but not
tumor cells. Samples were analyzed on a FACSCanto II
system (B-D) using FlowJo Software (TreeStar Inc.).
Activity of CD34-TRAIL? cells in non-obese diabetic/
severe combined immunodeficiency (NOD/SCID) mice
Six- to 8-wk-old female NOD/SCID mice (purchased from
Charles River, Milano, Italy, EU) were housed in our ani-
mal facilities at constant temperature and humidity, with
food and water given ad libitum. All animal procedures
were approved by the Ethics Committee for Animal
Experimentation of the Istituto Nazionale Tumori of Milan
according to the United Kingdom Coordinating Committee
on Cancer Research guidelines [16]. Two experiments were
performed to evaluate the anti-tumor activity of CD34-
TRAIL? cells in mice xenografted with 5 9 106 cells/
mouse of MDA-MB-231 cells injected subcutaneously
(s.c.) in the right flank. On day 14 after tumor inoculation,
when tumor volume was * 50 mm3, mice were randomly
divided into 2 groups (5 per group in experiment 1; 11 per
group in experiment 2). In experiment 1, mice were
injected intravenously (i.v.) with CD34-TRAIL? cells
(1 9 106 cells/mouse/injection) or PBS on days 14, 17, 21,
and 24, while in experiment 2, injections were identical to
those in experiment 1 except administered on days 14, 17,
28, and 31. Mice were monitored twice weekly for tumor
size and body weight. Tumors were measured with calipers
and tumor volume was calculated as: (D 9 d2)/2, where
D and d represent the longest and shortest diameters,
respectively. At 12 days after the last treatment, all mice in
experiment 1 and 5 of 11 of each group in experiment 2
were killed. After one week in the remaining 6 mice per
group tumors were surgically removed and animals were
killed 18 days later. Lungs from mice in experiment 2 were
evaluated for the presence of metastases.
The anti-metastatic effect of CD34-TRAIL? cells was
also investigated in an experimental metastasis model.
Eight-week-old female NOD/SCID mice were injected i.v.
with 1 9 106 MDA-MB-231 cells followed 4 h later by i.v.
injection with CD34-TRAIL? cells (1 9 106 cells/mouse;
4 mice), CD34? cells (1 9 106 cells/mouse; 4 mice), or
PBS (4 mice). At day 31 post-injection, mice were killed
and the number of pulmonary metastases was estimated.
Tumor and lung histology and immunohistochemistry
Formalin-fixed, paraffin-embedded tumor nodules were
sectioned at 4 lm, dewaxed, hydrated, and stained with
hematoxylin and eosin or processed for immunohisto-
chemistry with mouse anti-mouse CD31 antibody (PE-
CAM-1, clone D-11; 1:50, Santa Cruz Biotechnology, CA,
USA) after antigen retrieval in 1 mM EDTA at 95 C for
30 min or with monoclonal mouse anti-human CD45 anti-
body (clones 2B11 ? PD7/26; 1:100, Dako) after antigen
retrieval in citrate buffer, pH 6.0, at 95 C for 6 min.
Tumor necrosis was detected using TdT-mediated dUTP
nick-end-labeling (TUNEL) staining (Roche, Milano, Italy,
EU) according to the manufacturer’s instructions. Positive
signals were revealed by 3,30-diaminobenzidine staining,
and tumor sections were counterstained before analysis by
light microscopy.
To visualize lung metastases, 4-lm formalin-fixed,
paraffin-embedded lung sections were dewaxed, hydrated,
and stained with hematoxylin and eosin or processed for
immunohistochemistry with mouse anti-human vimentin
(clone V9; 1:400, Dako) after antigen retrieval with citrate
buffer, pH 6.0, at 95 C for 6 min. For each mouse, mean
number and size of lung metastases were evaluated in 3
microscopic fields (3.0 9 3.0 mm2) randomly selected in
each histological section. Metastases size expressed in lm
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was calculated using ImageJ software by determination of
the longest diameter using the scale bar as reference.
Analysis of stained sections
After TUNEL staining, tissue sections were acquired at
20 9 magnification with an automatic high-resolution
scanner (dotSlide System, Olympus, Tokyo, Japan) and
grouped according to non-overlapping red, green, and blue
(RGB) images in TIFF format (final resolution, 3.125 pix-
els/lm). Images were analyzed using the open source
imaging software ImageJ (http://rsb.info.nih.gov/ij/). Rou-
tines for image analysis were coded in ImageJ macro
language and executed on RGB images without further
treatment. For each experimental condition, three tissue
sections from each tumor nodule were analyzed. Images
were first treated for noise reduction using a median filter
with a 1.5 pixel radius. Necrotic and total tissue areas were
examined using different filter values under direct human
supervision. Black areas in final binary images were
quantified according to pixel counts to obtain a percentage
of necrotic areas expressed as: 100 9 (necrotic area/total
tissue area).
Tumor vasculature was evaluated in CD31-stained sec-
tions acquired at 400 9 magnification and using Aperio
ImageScope v11.1.2.752 at 2 9 magnification in vimentin-
stained sections.
Fig. 1 CD34-TRAIL? cell-induced toxicity in breast cancer cell
lines, Cell lines were incubated with CD34-TRAIL? or non-
transduced CD34? cells at effector:target cell ratio 1:1 for 48 h, or
left untreated. Cell death was measured by flow cytometry to assess
Annexin-V/PI labeling. a mTRAIL sensitivity, with each cell line
grouped according to breast cancer subtype. b Cell death of each cell
line untreated or after incubation with CD34-TRAIL? or non-
transduced CD34? cells. Data represent mean cell death ± SEM in
three independent experiments with each cell line. Differences
between CD34-TRAIL?-treated, non-transduced CD34?-treated and
untreated cells were compared by unpaired two-tailed t test.
*P \ 0.01, **P \ 0.001, ***P \ 0.0001
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Statistical analysis
Statistical analysis was performed with the statistical pack-
age Prism 5 (GraphPad Software, San Diego, CA, USA). In
all in vitro experiments, differences between untreated and
treated cells in apoptotic response were analyzed using the
unpaired (2-tailed) Student’s t test. The correlation between
the percentage of CD44?/CD24-/low cells and mTRAIL
sensitivity was evaluated by Pearson’s Chi-squared test and
the correlation between TRAIL receptor expression and
mTRAIL sensitivity, by Fisher’s exact test. Differences in
areas of necrosis and in mean number of lung metastases
between the two experimental mouse groups were analyzed
using the unpaired (2-tailed) Student’s t test. Differences
were considered significant at P B 0.05.
Results
Cell death induced by CD34-TRAIL? cells in breast
cancer cell lines
The cytotoxic activity of CD34-TRAIL? cells was evalu-
ated in 12 breast cancer cell lines representative of the
different breast cancer subtypes classified based on tran-
scriptional profiles as: ER? (MCF7, ZR-75-1, T47D,
BT-474, MDA-MB-361), HER2/neu? (SKBR3, MDA-
MB-453), and mesenchymal (MDA-MB-231, MDA-MB-
157, SUM-159) and basal (MDA-MB-468, HCC-1937) TN
[17, 18]. These cell lines reflect in some measure the
genetic heterogeneity present in primary breast cancer.
Remarkable levels of apoptotic cells were observed in
most of the cell lines upon co-culture with 1.5 9 105
CD34-TRAIL? cells at 1:1 effector/target cell ratio
(Fig. 1). The percentage of CD34-TRAIL? cell cytotox-
icity, corrected for that of non-transfected CD34? cells
(Fig. 1a), was highest in mesenchymal TN cell lines,
ranging from 75 to 43.5 %; in basal TN cell lines, sensi-
tivity ranged from 45.6 to 27.7 %. The apoptotic response
in ER? cell lines was lower than in TN lines and ranged
widely (44–0.1 %). In HER2? cell lines, sensitivity to
CD34-TRAIL? cells ranged from 42.7 to 13.8 %. Breast
cancer cell lines co-cultured with non-transduced CD34?
cells showed a similar apoptotic death as untreated cells
(Fig. 1b), indicating that the response did not depend on
the presence of CD34 per se. Co-culture experiments using
one representative cell line for each breast cancer subtype
(MDA-MB-231 for mesenchymal triple-negative subtype,
MDA-MB-468 for basal triple-negative subtype, ZR-75-1
for ER? subtype and SKBR3 for HER2?subtype) at
increasing effector:target ratios showed that CD34-TRAIL?
cells triggered cell death in a dose-dependent manner
(Supplemental Fig. 1), consistent with previous data [6].
Evaluation of the entire panel of breast cancer cell lines for
sensitivity to sTRAIL indicated no or only low sensitivity in
most cell lines, again consistent with previous results [19].
Supplementary Table 1 reports the comparison between
sTRAIL and CD34-TRAIL? cell cytotoxic activity.
Differential expression of the TRAIL-R1, -R2, -R3, and
-R4 receptors on the cell membrane of the cell lines,
evaluated in 3 independent experiments, did not appear to
account for the differences in sensitivity to mTRAIL, since
flow cytometry revealed, with few exceptions, only rela-
tively low-level expression of these death receptors
independent of tumor phenotype (Table 1); exceptions
included substantial levels of TRAIL-R2 in MDA-MB-231,
Table 1 Expression levels of
TRAIL receptors in breast
cancer cell lines
* Data are given as
mean ± SEM of the ratio
between mean fluorescence
intensity obtained with specific
anti-TRAIL receptor antibodies
and that of the corresponding
isotype control in 3 independent
experiments
Cell line TRAIL-R1 TRAIL-R2 TRAIL-R3 TRAIL-R4
TN mesenchymal
MDA-MD-231 1.18 ± 0.07* 3.89 ± 0.84 1.62 ± 0.10 2.25 ± 0.23
MDA-MD-157 1.11 ± 0.03 1.04 ± 0.01 0.99 ± 0.04 1.17 ± 0.03
SUM-159 0.95 ± 0.07 4.70 ± 0.21 1.06 ± 0.07 3.50 ± 0.40
TN basal
MDA-MD-468 1.07 ± 0.04 1.05 ± 0.03 1.02 ± 0.02 1.05 ± 0.03
HCC-1937 1.08 ± 0.04 1.09 ± 0.04 1.11 ± 0.06 1.04 ± 0.04
ER? luminal
ZR-75-1 1.03 ± 0.09 4.48 ± 0.49 3.30 ± 0.37 2.04 ± 0.06
T47D 1.21 ± 0.09 5.42 ± 1.55 2.63 ± 0.51 1.40 ± 0.19
MCF7 1.19 ± 0.10 1.43 ± 0.19 2.09 ± 0.11 1.13 ± 0.01
BT-474 1.07 ± 0.08 1.08 ± 0.08 1.05 ± 0.07 1.03 ± 0.03
MDA-MD-361 0.99 ± 0.06 0.98 ± 0.05 1.09 ± 0.04 0.97 ± 0.05
HER2?
SKBR3 1.01 ± 0.04 1.09 ± 0.04 1.08 ± 0.04 1.04 ± 0.02
MDA-MD-453 1.19 ± 0.17 1.12 ± 0.08 1.15 ± 0.09 1.08 ± 0.10
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SUM-159, T47D, and ZR-75-1 cells, TRAIL-R3 in MCF7,
T47D, and ZR-75-1 cells, and TRAIL-R4 in MDA-MB-
231, SUM-159, and ZR-75-1 cells. Expression of death-
inducing TRAIL-R1, TRAIL-R2, and the antagonistic
TRAIL-R3 and TRAIL-R4 did not correlate with sensi-
tivity to CD34-TRAIL? by Fisher’s exact test.
‘‘Stemness’’ and sensitivity to mTRAIL-induced
apoptosis
The cell subpopulation expressing cell surface markers
CD44?/CD24-/low with increased tumorigenicity has been
described as a population enriched in putative cancer stem
cells in human breast tumors [20]. Further studies indicated
that human breast cancer cell lines with mesenchymal
features are enriched in stem cell-like features [21, 22] and
recently Rahman et al. [19] demonstrated the strongest
sensitivity to sTRAIL by this breast cancer subtype. To test
whether the content of putative cancer stem cells was
associated with sensitivity to CD34-TRAIL? cells, we first
assessed the proportion of CD44?/CD24-/low cells in all
cell lines by flow cytometry. Analysis revealed a high
proportion of such cells in mesenchymal TN cell lines
(94.6 % in MDA-MB-231, 86 % in SUM-159, and 69.5 %
in MDA-MB-157), whereas a stem population was low
represented in ER?, HER2? or basal TN tumor cell lines,
except for the basal TN line HCC-1937, in which CD44?/
CD24-/low cells comprised about 29.8 % of cells (Fig. 2a).
Pearson’s Chi-squared test indicated a significant correla-
tion (r = 0.7047, P = 0.011) between CD34-TRAIL?
cytotoxic activity and the proportion of CD44?/CD24-/low
cells (Fig. 2b). Moreover, in vitro co-culture cytotoxicity
experiments using as targets two cell lines with different
percentages of CD44?/CD24-/low cells showed that CD34-
TRAIL? cells induced a decrease in the percentage of
viable CD44?/CD24-/low cells from 94.5 to 63.4 % in
MDA-MB-231 cells and from 1 to 0.4 % in SKBR3 cells,
indicating the selective cytotoxic activity of CD34-
TRAIL? cells. No decrease in CD44?/CD24-/low cells was
observed in response to CD34? cells.
Effects of CD34-TRAIL? on MDA-MD-231
subcutaneous xenograft tumors
MDA-MB-231 cells, which were sensitive to mTRAIL in
vitro and are able to metastasize spontaneously to lungs
[23], were used to evaluate the in vivo effect of CD34-
TRAIL? cells. In experiment 1 (Fig. 3, experiment 1),
NOD/SCID mice with established s.c. MDA-MB-231
tumors were randomized and inoculated i.v. with CD34-
TRAIL? cells (1 9 106 cells/mouse/injection) or PBS on
days 14, 17, 21, 24 after tumor cell injection. No significant
inhibition of tumor volume was observed in either mouse
group (Fig. 3, experiment 1, a). Consistent with a previous
finding in a model of hematological tumor [14] that intra-
tumor CD34-TRAIL? cells are not detectable beyond 48 h
after injection, we found no immunohistochemical staining
for the CD45 leukocyte marker indicative of CD34-
TRAIL? cells in tumor sections. Nevertheless, TUNEL
examination indicated a significant increase in necrotic
areas in tumors from CD34-TRAIL?-treated versus control
mice (19.2 ± 1.7 vs. 9.9 ± 1.0 %; P = 0.0003) (Fig. 3,
Fig. 2 Correlation between stemness and sensitivity to CD34-
TRAIL? cells, a content of putative cancer stem cells (percentage
of CD44?/CD24-/low) evaluated by flow cytometry. Each data point
represents the mean percentage of CD44?/CD24-/low in each cell line
from three-independent experiments. Cell lines were grouped by
subtype. Bars represent the mean percentage of CD44?/CD24-/low
for each breast cancer subtype. b Correlation analysis between
mTRAIL sensitivity and percentage of CD44?/CD24-/low cells using
Pearson’s Chi-squared test (P = 0.011; r = 0.7047)
462 Breast Cancer Res Treat (2012) 136:457–467
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experiment 1, b, c). As assessed based on immunohisto-
chemical staining for the CD31 endothelial marker, tumors
from CD34-TRAIL?-treated mice showed a remarkable
decrease in well-structured, branching vessels and a par-
allel increase in small endothelial sprouts as compared with
tumors from PBS-treated mice (Fig. 4). This finding is
suggestive of the attempt to rebuild the normal vasculature
structure after damage induced upon CD34-TRAIL?
treatment.
To test the effect of CD34-TRAIL? cells on the meta-
static potential of MDA-MB-231 tumors, 22 mice injected
s.c. with MDA-MB-231 were randomized into two groups
14 days later and treated i.v. with CD34-TRAIL? cells
(1 9 106 cells/mouse/injection) or PBS on days 14, 17, 28,
and 31. Five mice per group were killed 12 days after the
last treatment, when tumor volume was about 500 mm3.
Consistent with findings in experiment 1, also in the
experiment 2 the necrotic areas in tumors from CD34-
TRAIL?-treated mice in experiment 2 were also signifi-
cantly increased as compared with that in control mice
(23.7 ± 1.7 vs. 15.6 ± 1.7 %; P = 0.017) (Fig. 3, exper-
iment 2, b, c), without inhibition of tumor growth (Fig. 3,
experiment 2, a). These tumors also displayed a picture
suggestive of an attempt to restore normal vascular struc-
ture after CD34-TRAIL? treatment (not shown). Analysis
of metastases in lung sections stained with vimentin, a
Fig. 3 Effects of CD34-TRAIL? treatment on subcutaneous MDA-
MB231 tumors, Experiment 1. a Cytotoxic activity of CD34-TRAIL?
cells evaluated in NOD/SCID mice with established s.c. MDA-MB-
231 tumors. Mice (5 per group) were treated with PBS (open square)
or 106 CD34-TRAIL? cells (filled square) on days 14, 17, 21, and 24
(arrows). Data are given as mean tumor volume ± SD; b quantitation
of necrotic areas in tumor sections from CD34-TRAIL?- and PBS-
treated mice (5 mice/group) labeled for TUNEL assay. Necrotic areas
were analyzed using Image J software. Data are given as the ratio of
TUNEL-positive areas to total tumor tissue area 9 100. Boxes extend
from the 25th to 75th percentile, lines represent the median values,
and whiskers indicate the range of values. ***P = 0.0003 by
unpaired two-tailed t test; c hematoxylin-eosin and TUNEL staining,
revealing more extensive areas of necrosis in tumors of CD34-
TRAIL?- as compared to PBS-treated mice. Images for one
representative mouse per group are shown. Magnification, 9 2.
Experiment 2. a Same as in experiment 1 except for treatment
administration on days 14, 17, 28, and 31 (arrows); b same as in
experiment 1 except for *P = 0.017 by unpaired two-tailed t test;
c same as in experiment 1
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mesenchymal marker highly expressed in MDA-MB-231
cells, revealed 27 ± 22 metastases in the 5 control mice,
but no metastases in any of the 5 CD34-TRAIL? cell-
treated mice examined (P = 0.0079). One week after
metastasis analysis in these 10 mice, s.c. tumors were
surgically removed in the remaining 12 mice; 18 days
later, mice were killed and lungs were analyzed. The
average number of lung metastases was 312 in control mice
and 61 in CD34-TRAIL? cell-treated mice. This differ-
ence, although not statistically significant since 1 of the 6
control mice was completely devoid of lung metastases,
supports a role for CD34-TRAIL? cells in the control of
the spontaneous metastatic process. Note that metastases in
control mouse lungs were * 2-fold larger than in CD34-
TRAIL? cell-treated mice, with a mean size of 400 lm in
controls versus 200 lm in treated mice (Fig. 5).
In the model of experimental lung metastases, the mean
(± SD) number of pulmonary metastases in CD34-
TRAIL? cell-treated mice was also lower than in CD34?
cell- and PBS-treated mice (22 ± 6 in CD34? cell-treated
mice, 17 ± 7 in PBS-treated mice, and 3 ± 2 in CD34-
TRAIL? cell-treated mice; P = 0.0018 CD34-TRAIL?
cells versus CD34? cells; P = 0.018 CD34-TRAIL? cells
versus PBS).
Discussion
The use of stem and/or progenitor cells as delivery vehicles
for therapeutic gene products is emerging as a strategy to
improve the efficacy of currently available antitumor
therapies. Multiple potential sources of clinically useful
stem and progenitor cells have been identified, including
autologous and allogeneic embryonic, fetal, and adult
somatic cells from neural, adipose and mesenchymal tis-
sues [24–27]. Hematopoietic CD34? cells, which can be
easily mobilized, harvested, enriched, and genetically
engineered by adenovector transduction, represent a par-
ticularly feasible clinical strategy for systemic TRAIL
delivery. Furthermore, hematopoietic CD34? cells used as
vectors of TRAIL delivery reportedly home to or at least
engraft preferentially within tumors [14]. The specific
mechanisms underlying this tumor tropism of cell-based
delivery remain unclear, although it is plausible that dif-
ferent homing signals such as inflammatory chemoattrac-
tants and those from cytokines and adhesion molecules
present in the tumor microenvironment contribute to
tumor-homing of CD34-TRAIL? cells.
In the present study, we found that CD34-TRAIL? cells
exerted significant cell killing activity in breast cancer cell
lines representative of the biological and prognostic hetero-
geneity of the disease. Target cell death occurred by apoptosis
and did not correlate with the levels of death-inducing TRAIL
receptor expression. The latter finding is not surprising since
many tumors that express high levels of TRAIL-R1 and/or
TRAIL-R2 are resistant to soluble TRAIL [28–32]. Among
the cell lines examined, the stemness-enriched mesenchymal
TN cell lines were the most susceptible to apoptosis induced
by CD34-armed cells, and susceptibility to mTRAIL was
significantly correlated with stemness. Moreover, cytotoxicity
experiments indicated a selective cytotoxic activity of
mTRAIL against CD44?/CD24-/low cells. These findings
point to the potential usefulness of TRAIL-induced apoptosis
in the CD44?/CD24-/low fraction of tumors in overcoming the
refractory nature of these putative cancer stem cells to con-
ventional therapy. Indeed, other studies reported that cancer
stem cells are sensitive to the TRAIL-mediated cell death
pathway [19, 33].
In both of our in vivo experiments, CD34-TRAIL? cell
treatment induced significant necrosis as compared to
controls in s.c. growing tumors, but did not interfere with
tumor growth. This finding is not readily explained, since
proliferation of tumors is thought to depend on the estab-
lishment of tumor vasculature to provide nutrients required
for cancer cell expansion [34]. In our model, consistent
with that described in-depth in an s.c. multiple myeloma
model [14], CD34-TRAIL? cell treatment appeared to
induce endothelial damage in the tumor but without the
tumor growth inhibition observed in hematological tumors
[14]. It is possible that MDA-MB-231 cells overcome the
effect of mTRAIL on endothelial cells through the for-
mation of fluid-conducting networks by non-endothelial
cells as a result of vasculogenic mimicry, a feature
Fig. 4 Effects of CD34-TRAIL? cell treatment on tumor vascula-
ture, Immunohistochemical analysis of the intra-tumoral vascular
network of PBS- and CD34-TRAIL? cell-treated tumor-bearing mice
revealed an abundance of poorly structured microvessels and
endothelial sprouts (a and b, arrows) in the tumor vascularity of
mTRAIL-treated mice in contrast to the branching vessels character-
izing control mice (c and d, arrows). Representative areas of four
anti-CD31 immunostained sections are shown. Original magnifica-
tions, 9 20; bar 100 lm; and 9 40; bar 50 lm
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associated with the pluripotent gene expression pattern in
aggressive tumor cells and described for different tumors,
including breast [34, 35]. Indeed, no significant inhibition
of MDA-MB-231 tumor growth was observed in mice
injected with these cells in the mammary fat-pad and
treated with the anti-vascular endothelial growth factor A
(VEGF-A) antibody bevacizumab (not shown).
Despite no activity of CD34-TRAIL? cells on tumor
growth rate, mice treated with these cells and sacrificed
when the s.c. tumor was relatively small showed no lung
metastases, while lung metastases were present in all
control mice bearing s.c. tumors of superimposable size.
The inability of CD34-armed cells to interfere with the
growth rate of s.c. tumors versus their anti-metastatic
activity may be explained by their ability to induce a
selective elimination among CD44?/CD24-/low cells of
those crucial for the metastatic process, but not of those
involved in the continuing growth of a subcutaneous tumor.
Further studies are needed to determine whether the
inhibition of metastases by CD34-TRAIL? cells is rela-
ted to their effect on stem cells present in the primary
s.c. tumor or on stem cells that have already migrated to
the lungs. In any case, the ability of CD34-armed cells
to mediate a loss of function of stem cell metastatic
activity points to the value of treatment with CD34-
TRAIL? cells, suggesting their possible use in adjuvant
therapy. Our results on the ability of TRAIL-expressing
CD34? cells to subvert the breast cancer metastatic
process are consistent with the reported significant
reduction in metastatic tumor burden upon treatment
with inducible TRAIL-expressing bone marrow-derived
mesenchymal stem cells [36], although that analysis was
Fig. 5 Effects of CD34-TRAIL? cell treatment on lung metastases,
Excised lungs from CD34-TRAIL?cell- and PBS-treated mice
were analyzed for the presence of metastases by hematoxylin and
eosin (H/E) and immunohistochemical staining for vimentin, a
mesenchymal marker highly expressed in MDA-MB-231 cells.
a Mice killed 12 days after the last treatment (no surgery); b Mice
killed18 days after surgical removal of the tumor (surgery). Images
are of one representative mouse for each experimental group. Original
magnifications, 9 4; and 9 20
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performed only in mice i.v.-injected with tumor cells,
while our results were also obtained in spontaneous lung
metastases models.
While the selective targeting of cancer stem cells by
CD34-armed cells remains to be confirmed, the correlation
between in vitro susceptibility to mTRAIL and amount of
tumor stem cells, together with the CD34-TRAIL? cell-
induced inhibition of the metastatic process, point to
CD34-armed cell treatment as a viable approach to eradi-
cate stem tumor cells before the onset of overt metastases.
Acknowledgments This research was supported by Associazione
Italiana Ricerca sul Cancro (AIRC).
Conflict of interest The authors report no conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Jin Z, El-Deiry WS (2005) Overview of cell death signaling
pathways. Cancer Biol Ther 4:139–163
2. Debatin KM, Stahnke K, Fulda S (2003) Apoptosis in hemato-
logical disorders. Semin Cancer Biol 13:149–158
3. Krammer PH (2000) CD95’s deadly mission in the immune
system. Nature 407:789–795
4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl
JK, Sutherland GR, Smith TD, Rauch C, Smith CA (1995)
Identification and characterization of a new member of the TNF
family that induces apoptosis. Immunity 3:673–682
5. Ashkenazi A (2008) Directing cancer cells to self-destruct
with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:
1001–1012
6. Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P,
Milanesi M, Magni M, Morelli D, Gloghini A, Carbone A, Gianni
AM (2006) Antitumor activity of human CD34 ? cells express-
ing membrane-bound tumor necrosis factor-related apoptosis-
inducing ligand. Hum Gene Ther 17:1225–1240
7. Lavazza C, Carlo-Stella C, Di Nicola M, Longoni P, Milanesi M,
Magni M, Gianni AM (2007) Highly efficient gene transfer into
mobilized CD34 ? hematopoietic cells using serotype-5 adeno-
viral vectors and BoosterExpress Reagent. Exp Hematol 35:
888–897
8. Verfaillie CM (1998) Adhesion receptors as regulators of the
hematopoietic process. Blood 92:2609–2612
9. Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the
crosstalk between tumor cells and their microenvironment. Blood
107:1761–1767
10. Jin H, Aiyer A, Su J, Borgstrom P, Stupack D, Friedlander M,
Varner J (2006) A homing mechanism for bone marrow-derived
progenitor cell recruitment to the neovasculature. J Clin Invest
116:652–662
11. Tavassoli M, Minguell JJ (1991) Homing of hemopoietic pro-
genitor cells to the marrow. Proc Soc Exp Biol Med 196:367–373
12. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L,
Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z,
Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D,
Shmelkov SV, Jensen KK, Rafii S, Lyden D (2005) VEGFR1-
positive haematopoietic bone marrow progenitors initiate the pre-
metastatic niche. Nature 438:820–827
13. Aboody KS, Najbauer J, Danks MK (2008) Stem and progenitor
cell-mediated tumor selective gene therapy. Gene Ther 15:
739–752
14. Lavazza C, Carlo-Stella C, Giacomini A, Cleris L, Righi M, Sia
D, Di Nicola M, Magni M, Longoni P, Milanesi M, Francolini M,
Gloghini A, Carbone A, Formelli F, Gianni AM (2010) Human
CD34 ? cells engineered to express membrane-bound tumor
necrosis factor-related apoptosis-inducing ligand target both
tumor cells and tumor vasculature. Blood 115:2231–2240
15. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H,
Okumura K, Yagita H (1999) Involvement of TNF-related
apoptosis-inducing ligand in human CD4 ? T cell-mediated
cytotoxicity. J Immunol 162:2639–2647
16. (1998) United Kingdom Co-ordinating Committee on Cancer
Research (UKCCCR). Guidelines for the welfare of animals in
experimental neoplasia (second edition). Br J Cancer 77:1–10
17. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark
L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries
S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson
DG, Waldman FM, McCormick F, Dickson RB, Johnson MD,
Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of
breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell 10:515–527
18. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F,
Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA
(2009) Anti-epithelial cell adhesion molecule antibodies and the
detection of circulating normal-like breast tumor cells. J Natl
Cancer Inst 101:61–66
19. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer
PS, Lipkowitz S (2009) TRAIL induces apoptosis in triple-neg-
ative breast cancer cells with a mesenchymal phenotype. Breast
Cancer Res Treat 113:217–230
20. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF
(2003) Prospective identification of tumorigenic breast cancer
cells. Proc Natl Acad Sci USA 100:3983–3988
21. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz
JI, He X, Perou CM (2010) Phenotypic and molecular charac-
terization of the claudin-low intrinsic subtype of breast cancer.
Breast Cancer Res 12:R68
22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY,
Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL,
Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithe-
lial-mesenchymal transition generates cells with properties of
stem cells. Cell 133:704–715
23. Tang X, Sun Z, Runne C, Madsen J, Domann F, Henry M, Lin F,
Chen S (2011) A critical role of Gbetagamma in tumorigenesis
and metastasis of breast cancer. J Biol Chem 286:13244–13254
24. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS
(2002) The use of interleukin 12-secreting neural stem cells for
the treatment of intracranial glioma. Cancer Res 62:5657–5663
25. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-
Hansen M, Bekele BN, Champlin RE, Andreeff M (2004) Mes-
enchymal stem cells: potential precursors for tumor stroma and
targeted-delivery vehicles for anticancer agents. J Natl Cancer
Inst 96:1593–1603
26. Wei J, Blum S, Unger M, Jarmy G, Lamparter M, Geishauser A,
Vlastos GA, Chan G, Fischer KD, Rattat D, Debatin KM, Hatz-
opoulos AK, Beltinger C (2004) Embryonic endothelial progen-
itor cells armed with a suicide gene target hypoxic lung
metastases after intravenous delivery. Cancer Cell 5:477–488
27. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner
C (2007) Adipose tissue-derived human mesenchymal stem cells
466 Breast Cancer Res Treat (2012) 136:457–467
123
mediated prodrug cancer gene therapy. Cancer Res 67:
6304–6313
28. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC,
Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W,
Krammer PH, Walczak H (2004) Enhanced caspase-8 recruit-
ment to and activation at the DISC is critical for sensitisation of
human hepatocellular carcinoma cells to TRAIL-induced apop-
tosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl
1):S86-96
29. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S
(1999) Chemotherapy augments TRAIL-induced apoptosis in
breast cell lines. Cancer Res 59:734–741
30. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK (2003)
Synergistic interactions of chemotherapeutic drugs and tumor
necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on
apoptosis and on regression of breast carcinoma in vivo. Cancer
Res 63:5390–5400
31. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer
K, Walczak H (2005) Proteasome inhibition sensitizes hepato-
cellular carcinoma cells, but not human hepatocytes, to TRAIL.
Hepatology 42:588–597
32. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ,
Zhang S, Carpenter M, LoBuglio AF (2003) Antitumor efficacy
of TRA-8 anti-DR5 monoclonal antibody alone or in combination
with chemotherapy and/or radiation therapy in a human breast
cancer model. Clin Cancer Res 9:3731–3741
33. Li M, Knight DA, Smyth MJ, Stewart TJ (2012) Sensitivity of a
novel model of mammary cancer stem cell-like cells to TNF-
related death pathways. Cancer Immunol Immunother 61(8):
1255–1268
34. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, Yao Z, Dong
XY, Zhao N, Liu N (2012) CD133(?) cells with cancer stem cell
characteristics associates with vasculogenic mimicry in triple-
negative breast cancer. Oncogene. doi:10.1038/onc.2012.85
35. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G,
Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De MR
(2010) Tumour vascularization via endothelial differentiation of
glioblastoma stem-like cells. Nature 468:824–828
36. Loebinger MR, Eddaoudi A, Davies D, Janes SM (2009) Mes-
enchymal stem cell delivery of TRAIL can eliminate metastatic
cancer. Cancer Res 69:4134–4142
Breast Cancer Res Treat (2012) 136:457–467 467
123
